Kalbe Farma announced IDR 500 billion buyback of Kalbe Farma stock

Published on 10/13/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales hit IDR 19.47 trillion, up 14.04 percent in first-half 2026. Kalbe Farma stock costs EUR 0.04 on October 13, 2026, bid EUR 0.03, ask EUR 0.05.

Kalbe Farma announced an IDR 500 billion buyback program on September 15, 2026.
First-half 2026 sales reached IDR 19.47 trillion, up 14.04 percent year on year.
Kalbe Farma stock was EUR 0.04 at Lang & Schwarz on October 13, 2026, with a EUR 0.03 bid and EUR 0.05 ask.
The buyback period is scheduled to run through December 17, 2026.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma (ID1000125107) was trading at EUR 0.04 at Lang & Schwarz on October 13, 2026, at 10:13 a.m. CEST, between a EUR 0.03 bid and a EUR 0.05 ask. On September 15, 2026, BCA Sekuritas reported that Kalbe Farma had announced an IDR 500 billion share buyback funded from internal cash.

Three dated Kalbe Farma events

On August 1, 2026, Liputan6 reported first-half sales of IDR 19.47 trillion, up 14.04 percent from the same period of 2025, while net income fell 2.70 percent to IDR 1.97 trillion. On September 15, 2026, BCA Sekuritas said the planned buyback could lift pro forma earnings per share to IDR 81.44 from IDR 80.51 for fiscal year 2025. On October 13, 2026, Bisnis.com reported KLBF at IDR 770 during the opening session.

What does the buyback change?

The capital action is material because the company plans to spend IDR 500 billion while reducing the number of shares in circulation. Kontan reported on September 28, 2026, that UBS Sekuritas Indonesia analyst Permada Darmono estimated the buyback could support earnings per share by 1.10 percent based on fiscal year 2025 performance. The same report said the program may reduce interest income by IDR 8.40 billion, while UBS projected 2026 revenue of IDR 40.42 trillion and net income of IDR 3.56 trillion.

Buyback runs through December 17

Liputan6 reported that the buyback is scheduled to run from September 17 through December 17, 2026, using internal funds and transactions on the Indonesia Stock Exchange. The report also put first-half 2026 gross profit at IDR 7.31 trillion, up 4.45 percent year on year, while cost of sales rose 20.71 percent to IDR 12.16 trillion.

EUR 0.04 at Lang & Schwarz

Kalbe Farma stock was trading at EUR 0.04 at Lang & Schwarz on October 13, 2026, at 10:13 a.m. CEST. The quote stood between a EUR 0.03 bid and a EUR 0.05 ask, while the Indonesian market level reported by Bisnis.com was IDR 770 during the opening session on October 13, 2026.

The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.